Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (191-200 of 324) with videos related to

Pageof 33
Sort By:
Pharmacogenetics and Genomics|April 13, 2006
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavirMark A Boyd, Preeyaporn Srasuebkul, Kiat Ruxrungtham, et al.
Plos One|October 17, 2013
Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiencyDenise C Hsu, Stephen J Kerr, Thatri Iampornsin, et al.
BMC Public Health|September 6, 2014
The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methodsBenjamin R Bavinton, Fengyi Jin, Garrett Prestage, et al.
AIDS (London, England)|January 9, 2018
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapyGwamaka E Mwasakifwa, Cecilia Moore, Dianne Carey, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|March 3, 2007
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimensStephen J Kerr, Chris Duncombe, Anchalee Avihingsanon, et al.
The Journal of Infectious Diseases|October 17, 2006
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012)Mark A Boyd, Narendra M Dixit, Umaporn Siangphoe, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2010
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair studyRebekah L Puls, Preeyaporn Srasuebkul, Kathy Petoumenos, et al.
The Journal of Infection|December 12, 2013
Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapyDenise C Hsu, Stephen J Kerr, Parawee Thongpaeng, et al.
International Journal of Radiation Oncology, Biology, Physics|November 30, 2018
Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?John T Lucas, M Beth McCarville, David A Cooper, et al.
Pageof 33

Showing results (191-200 of 324) with videos related to

Sort By:
Pageof 33
Pharmacogenetics and Genomics|April 13, 2006
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavirMark A Boyd, Preeyaporn Srasuebkul, Kiat Ruxrungtham, et al.
Plos One|October 17, 2013
Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiencyDenise C Hsu, Stephen J Kerr, Thatri Iampornsin, et al.
BMC Public Health|September 6, 2014
The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methodsBenjamin R Bavinton, Fengyi Jin, Garrett Prestage, et al.
AIDS (London, England)|January 9, 2018
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapyGwamaka E Mwasakifwa, Cecilia Moore, Dianne Carey, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|March 3, 2007
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimensStephen J Kerr, Chris Duncombe, Anchalee Avihingsanon, et al.
The Journal of Infectious Diseases|October 17, 2006
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012)Mark A Boyd, Narendra M Dixit, Umaporn Siangphoe, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2010
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair studyRebekah L Puls, Preeyaporn Srasuebkul, Kathy Petoumenos, et al.
The Journal of Infection|December 12, 2013
Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapyDenise C Hsu, Stephen J Kerr, Parawee Thongpaeng, et al.
International Journal of Radiation Oncology, Biology, Physics|November 30, 2018
Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?John T Lucas, M Beth McCarville, David A Cooper, et al.
Pageof 33